HRTS News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

HR

AUM

N/A

Volume

2.36K

Yield

1.28%

Chart Earnings News About Dividends Insider Filings

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to WinAt the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic. The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector.Zacks Investment Research · Oct 1, 2026

EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'Novo Nordisk faces political pressure over high U.S. prices for its weight-loss drugs, Ozempic and Wegovy, ahead of the 2024 election. The company's CEO blamed pharmacy benefit managers (PBMs) for the high consumer costs, despite potential manufacturer price reductions.Benzinga · Sep 25, 2024

ETFs to Profit from the Weight Loss Drug BoomThe market for GLP-1 drugs could soar to $130 billion by 2030Zacks Investment Research · Jun 4, 2024

Play These New ETFs to Tap Lucrative Weight Loss Drug MarketGlobal obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.Zacks Investment Research · May 22, 2024

Healthcare ETFs for the Weight-Loss Drug Boom & BeyondWe discuss attractive investment opportunities within the healthcare industry.Zacks Investment Research · Apr 8, 2024

Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only GrowingDavid Song, PM of the Cardiovascular and Metabolic ETF (NASDAQ: HRTS) for Tema ETFs, was recently interviewed by Benzinga. Tema is an active investment adviser focused on differentiated strategies managed by experienced investment professionals offered through ETFs and SMAs. ...Full story available on Benzinga.comBenzinga · Jan 29, 2024

Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment MarketHow important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic. Those with obesity drugs already on the market have proved, through their share price moves in the past months, what it means to have this type of treatment on your roster. Novo Nordisk (NYSE:NVO) — with two obesity drugs Ozempic and Wegovy — has jumped by around 300% since it bought Ozempic to the market in 2019, while Eli Lilly (NYSE:LLY) is up nearly 90% since the launch of Mounjaro in May 2022. By contrast, Pfizer (NYSE:PFE), which announced only a few days ago that it was stopping development of a twice daily version of its experimental weight loss pill, is down 41% this year. Pfizer does still plan to bring a once-a-day pill ...Full story available on Benzinga.comBenzinga · Dec 4, 2023

EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The FadsTema ETFs is redefining thematic investing by prioritizing long-term structural trends and precision in security selection, diverging from the industry norm of chasing short-lived market fads. This innovative approach was the focal point of a virtual session hosted by Benzinga’s “ETFs Unlocked,” moderated by Benzinga’s Aaron Bry. Yuri Khodjamirian, CFA, chief investment officer at Tema ETFs, revealed the company’s innovative approach to thematic investing, addressing common pitfalls in passive funds and showcasing their latest offerings in various market themes including product reshoring in the U.S., luxury goods, and cardio-metabolic diseases. Tema ETFs: Pioneering Precision in Thematic Investing Established two years ago with six funds in the market, Tema ETFs has carved a niche in the ETF landscape. “We want to be in structural long term growing areas of the market where we really believe there’s an investment merit over multiple decades,” Khodjamirian said. Emphasizing long-term structural themes, they use expert analysis for security selection, ensuring portfolios are precisely focused on high-quality ...Full story available on Benzinga.comBenzinga · Dec 1, 2023

HR

HRTSTema ETF Trust Tema Heart & Health ETF

HRTS

Pay with—

Available Balance0.00

Your PositionYou don't own any HRTS yet.

Related Tickers

Earnings

Dividends

Last · Dec 10Annual

Amount$0.47

Yield1.28%

Annual$0.47